Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Teresa R. Wagner, E. Ostertag, Philipp D. Kaiser, et al.
EMBO Reports (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Matthias Becker, Alex Dulovic, Daniel Junker, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 150
Nanobodies: Robust miniprotein binders in biomedicine
Jeffrey Yong Joon Kim, Zhe Sang, Yufei Xiang, et al.
Advanced Drug Delivery Reviews (2023) Vol. 195, pp. 114726-114726
Open Access | Times Cited: 44
Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
Justin D. Walter, Melanie Scherer, Cedric A. J. Hutter, et al.
EMBO Reports (2022) Vol. 23, Iss. 4
Open Access | Times Cited: 40
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Wei‐Hung Chen, Agnes Hajduczki, Elizabeth J. Martinez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
Nanobody-Based Lateral Flow Immunoassay for Rapid Antigen Detection of SARS-CoV-2 and MERS-CoV Proteins
Yuli Peng, Ya-Ning Huang, Fabian Kießling, et al.
ACS Synthetic Biology (2025)
Closed Access | Times Cited: 1
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, et al.
Microbial Cell Factories (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma, Xinghai Zhang, Peiyi Zheng, et al.
Cell Research (2022) Vol. 32, Iss. 9, pp. 831-842
Open Access | Times Cited: 29
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 20
Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)
Salma Bessalah, Samira Jebahi, Naceur Mejri, et al.
3 Biotech (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 33
Superimmunity by pan-sarbecovirus nanobodies
Yufei Xiang, Wei Huang, Hejun Liu, et al.
Cell Reports (2022) Vol. 39, Iss. 13, pp. 111004-111004
Open Access | Times Cited: 28
Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review
Hamid Aria, Fatemeh Mahmoodi, Hooria Seyedhosseini Ghaheh, et al.
Analytical Biochemistry (2022) Vol. 640, pp. 114546-114546
Open Access | Times Cited: 25
Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications
Ki Sung Park, Tae-In Park, Jae Eon Lee, et al.
Biosensors (2024) Vol. 14, Iss. 3, pp. 146-146
Open Access | Times Cited: 6
Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells
Bjoern Traenkle, Philipp D. Kaiser, Stefania Pezzana, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 30
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus
Xuemei Feng, Hu Wang
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 7, pp. 925-942
Open Access | Times Cited: 11
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
Teresa R. Wagner, Daniel Schnepf, Julius Beer, et al.
EMBO Reports (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 25
Nanobodies – Little helpers unravelling intracellular signaling
Teresa R. Wagner, Ulrich Rothbauer
Free Radical Biology and Medicine (2021) Vol. 176, pp. 46-61
Closed Access | Times Cited: 24
Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
Qilong Tang, Raymond J. Owens, James H. Naismith
Viruses (2021) Vol. 13, Iss. 11, pp. 2214-2214
Open Access | Times Cited: 24
Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis
Xing Liu, Jianxin Sui, Cui Li, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 537-551
Open Access | Times Cited: 18
Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
Gennady M. Verkhivker
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 2928-2928
Open Access | Times Cited: 16
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
Teresa R. Wagner, Simone Blaess, Inga B. Leske, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
Katy Cornish, Jiandong Huo, Luke Jones, et al.
Open Biology (2024) Vol. 14, Iss. 6
Open Access | Times Cited: 3
HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1
Marius Gramlich, Henry C.W. Hays, Scott Crichton, et al.
Antibodies (2021) Vol. 10, Iss. 1, pp. 11-11
Open Access | Times Cited: 19
Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, et al.
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top